Page 78 - 2022_03-Haematologica-web

O. Benjamini et al.
References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8): 727-733.
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2 603-2615.
3. https://www.fda.gov/emergency-pre- paredness-and-response/coronavirus-dis- ease-2019-covid-19/pfizer-biontech-covid- 19-vaccine [last accessed May 19, 2021]
4. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-1423.
5. Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11(1):57-70.
6. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
7. Scarfo L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortali- ty in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354- 2363.
8.FurstenauM,LangerbeinsP,DeSilvaN,et al. COVID-19 among fit patients with CLL treated with venetoclax-based combina-
tions. Leukemia. 2020;34(8):2225-2229. 9.Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experi-
ence. Blood. 2020;136(10):1134-1143.
10. Whitaker JA, Parikh SA, Shanafelt TD, et al. The humoral immune response to high- dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
Vaccine. 2021;39(7):1122-1130.
11. Svensson T, Kattstrom M, Hammarlund Y,
et al. Pneumococcal conjugate vaccine trig- gers a better immune response than pneu- mococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia. A randomized study by the Swedish CLL group. Vaccine. 2018;36(25): 3701-3707.
12. Zent CS, Brady MT, Delage C, et al. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia. 2021;35(6):1788-1791.
13. Pleyer C, Ali MA, Cohen JI, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185- 189.
14. Shadman M, Ujjani C. Vaccinations in CLL: implications for COVID-19. Blood. 2021;137(2):144-146.
15.Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;(33):388-396.
16.Herishanu Y, Avivi A, Aharon A, et al.
17.
18.
19.
20.
21.
Efficacy of the BNT162b2 mRNA COVID- 19 vaccine in patients with chronic lym- phocytic leukemia. Blood. 2021;137(23): 3165-3173.
Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV- 2 non-responding seronegative subpopula- tion. EClinicalMedicine. 2020;29;100651. Perkmann T, Perkmann-Nagele N, Breyer MK, et al. Side-by-side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity. Clin Chem. 2020;66(11):1405-1413.
Dieterle ME, Haslwanter D, Bortz RH 3rd, et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe. 2020;28(3):486-496. Ribbing J, Nyberg J, Caster O, Jonsson EN. The lasso - a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2007;34(4):485-517.
Kim SM, Kim Y, Jeong K, Jeong H, Kim J. Logistic LASSO regression for the diagnosis of breast cancer using clinical demographic data and the BI-RADS lexicon for ultra- sonography. Ultrasonoography. 2018;37 (1):36-42.
22. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476-488.
23. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599.
634
haematologica | 2022; 107(3)